Class summary at a glance.

Every drug in the Lipopeptide Antibacterial class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $188.0Mcombined across class
Total Rx claims: 233K56K unique beneficiaries
Generic mfrs (active): 16across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Daptomycin

Brand: DAPZURA RT · 233K Part D claims (CY24) · 56K beneficiaries · First FDA approval: 2018-01-15

16 generic mfrs 0 plans require PA

Low NADAC$13.42

→

Avg plan cost$18.11

Part D spend $188.0M 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Daptomycin In Sodium

— Part D claims (CY24) · First FDA approval: 2022-01-25

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.